| Literature DB >> 24972336 |
Subha Mukherjee1, Wilfred A van der Donk.
Abstract
LanthiEntities:
Mesh:
Substances:
Year: 2014 PMID: 24972336 PMCID: PMC4111213 DOI: 10.1021/ja504692v
Source DB: PubMed Journal: J Am Chem Soc ISSN: 0002-7863 Impact factor: 15.419
Figure 1(A) Generic scheme for lanthipeptide biosynthesis. (B) Common post-translational modifications in lanthipeptides.
Figure 2Structures of prochlorosins 2.8 and 3.3. The fragments of the Lan/MeLan residues originating from Cys are in red, and those originating from Ser/Thr residues are in blue.
Figure 3Strategy for determination of directionality of dehydration using [2,3,3-2H]-Ser or [2,3-2H]-Thr residues. (A) Dehydration of Ser incurs a loss of 18 Da. (B) Dehydration of labeled Ser results in a loss of 19 Da. (C) Dehydration of Thr incurs a loss of 18 Da. (D) Dehydration of labeled Thr results in a loss of 19 Da. By tracking which dehydration involves a loss of 19 Da, directionality of dehydration can be established.[28]
Figure 4Schematic representation of ProcA2.8 leader-AA-MESNa thioester (1), ProcA2.8 core peptide Δ1–2 with Ser13 replaced with [2,3,3-2H]-Ser (2), and ProcA2.8 core peptide Δ1–2 with Ser9 replaced with [2,3,3-2H]-Ser (3).
Figure 5Directionality of dehydration of wt ProcA2.8. (A) Structure of ProcA2.8 precursor peptide 4 assembled using EPL with Ser13 replaced with [2,3,3-2H]-Ser. (B) MALDI-TOF MS of 4 partially dehydrated by ProcM and digested by GluC. (C) Structure of ProcA2.8 precursor peptide 5 assembled using EPL with Ser9 replaced with [2,3,3-2H]-Ser. (D) MALDI-TOF MS of 5 partially dehydrated by ProcM and digested by GluC.
Figure 6Structure of building block 6 used to attach an alkyne at the C-terminus of the leader peptide by EPL. Building block 7 was used for installation of a photocleavable triazole linker between the leader and the core peptides. The building block 8 was used to facilitate the click reaction via a copper-chelating group.
Figure 7Directionality of dehydration in ProcA2.8 analogues. (A) Structure of ProcA2.8 precursor peptide 9 with Ser13 replaced with [2,3,3-2H]-Ser. (B) MALDI-TOF MS of 9 partially dehydrated by ProcM and after LysC cleavage. (C) Structure of ProcA2.8 precursor peptide 10 with Ser9 replaced with [2,3,3-2H]-Ser. (D) MALDI-TOF MS of 10 partially dehydrated by ProcM and after LysC cleavage.
Figure 8Directionality of dehydration of ProcA3.3 analogues containing a triazole linker. (A) Structure of ProcA3.3 analogue 12 with Thr18 replaced with [2,3-2H]-Thr. (B) MALDI-TOF MS of 12 partially dehydrated by ProcM and digested by GluC. (C) Structure of ProcA3.3 analogue 13 with Thr11 replaced with [2,3-2H]-Thr. (D) MALDI-TOF MS of 13 partially dehydrated by ProcM and digested by GluC.
Figure 9Probing non-enzymatic cyclization in ProcA2.8. (A) Non-enzymatic cyclization of the A-ring in the presence of the enzymatically preinstalled B-ring. Reagents and conditions: (i) HEPES, ATP, TCEP, MgCl2, substrate 14 (50 μM), ProcM (30 μM); (ii) ProcM was removed, the intermediate 18 was desalted and lyophilized, dissolved in 0.1% TFA, and irradiated; (iii) the peptide was dissolved in HEPES buffer (pH 8.0) to allow non-enzymatic cyclization followed by treatment with iodoacetamide. (B) MALDI-TOF MS analysis showed that non-enzymatic cyclization was slow and incomplete, as indicated by the presence of IAA adduct 22. (C) Non-enzymatic cyclization of the B-ring in ProcA2.8 in the presence of enzymatically preinstalled A-ring. Reagents and conditions: (i) HEPES, ATP, TCEP, MgCl2, ProcM (30 μM), substrate 15 (50 μM); (ii) ProcM was removed, intermediate 19 was irradiated with UV light and lyophilized; (iii) the lyophilized peptide was dissolved in solution containing all components in (i) except ProcM, digested with LysC and treated with excess iodoacetamide. (D) MALDI-TOF MS analysis showed that non-enzymatic cyclization was incomplete, as indicated by the presence of IAA adduct 23.
Figure 10Probing non-enzymatic cyclization in ProcA3.3. (A) Non-enzymatic cyclization of the A-ring in the presence of enzymatically preinstalled B-ring. Reagents and conditions: (i) HEPES, ATP, TCEP, MgCl2, substrate 16 (50 μM), ProcM (20 μM); (ii) ProcM was removed and the intermediate 20 was irradiated with UV light and lyophilized; (iii) the lyophilized peptide was dissolved in assay solution containing all components in (i) with or without ProcM, digested by LysC, and treated with iodoacetamide. (B) MALDI-TOF MS of solution obtained after treatment in (iii). (C) ProcM assay of substrate 17 generated a mixture of intermediates 21 and 25. (D) ProcM was removed from the mixture of 21 and 25, and the product mixture was irradiated with UV light and lyophilized. The peptide mixture was dissolved in solution containing all ProcM assay components with or without ProcM. The products were then treated with LysC and IAA. The MALDI-TOF MS spectra of the two assays are presented.
Figure 11Scheme for the exchange assay. Substrate is modified by ProcM in deuterium-labeled buffer to generate product with one deuterium per Lan/MeLan. Exchange of the installed deuterium was then investigated by treating the modified precursor peptide with ProcM in unlabeled buffer. Exchange can occur by abstraction of deuterium followed by protonation (solid blue arrows) or by retro-Michael-type addition (dashed blue arrow) and recyclization.
Figure 12Deuterium incorporation and exchange in ProcA2.8 and ProcA3.3. (A) Structure of GluC cleaved ProcA2.8 core peptide fragment incorporating two deuteriums. Residues in purple originate from the leader peptide. (B) MALDI-TOF MS of GluC cleaved fragment of deuterium-labeled ProcA2.8 (50 μM) after assay without (blue trace) and with ProcM (20 μM) treatment in aqueous buffer (red trace). (C) GluC digested ProcA3.3 core peptide incorporating two deuteriums. Residues in purple originate from the leader peptide. (D) MALDI-TOF MS of GluC digested fragment of modified deuterium-labeled ProcA3.3 (100 μM) without aqueous ProcM treatment (blue trace) and with aqueous ProcM (40 μM) treatment (red trace).